Innovating the next generation of immunological therapeutics

TLA Competitive Profile

TLA greatly reduces the risk for adverse side effects, has no loss of effect or resistance build up, and requires no systematic exposure to drugs. Following are some of the key advantages of TLA.

  • No Introduction of Foreign Substances: TLA does not introduce small molecules or proteins into the body as is the case with the current treatments such as steroids, anti –TNF-a, CCR-9 inhibitors, and other drugs in the pipeline from different research groups.

  • Extracorporeal Treatment: TLA is a treatment that takes place extracorporeally (outside of the body) – removing cells that cause harm without adding any cells or molecules to the system.

  • No Immune Activation: The contents of the column have been thoroughly tested, and do not cause any alteration or activation of the blood in immunological tests. Compared with other cell therapies blood is not removed for an extended period of time, changed in composition, and blood cells are not stimulated.   

  • No Immune Suppression: Cells essential for a normal immune defence in the patient are not taken away and pathways important for a normal defence against Cancer or Chronic infections are not blocked.

    • No Toxicity: The chemotactic substance (a chemokine) does not activate the immune system. The chemokine has a very high affinity for pro-inflammatory cells, usually >1000 times more than antibodies, and in the small amounts used it would not cause any harm even if injected into the body.

    • Personalised Treatment: Treatment can be stopped after removal of enough cells for restoring immune homeostasis (immunological balance). Specific cells in the blood can be measured and prophylactically treated before relapse.